View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 15, 2020

NIH trials hydroxychloroquine plus azithromycin for Covid-19

The US’ National Institutes of Health (NIH) has started a Phase IIb clinical trial to assess malaria drug hydroxychloroquine plus the antibiotic azithromycin to treat Covid-19.

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is funding the study, which is being performed by the NIAID-funded AIDS Clinical Trials Group (ACTG).

Teva Pharmaceuticals will supply drugs for the study, which will involve around 2,000 adult patients at participating ACTG sites across the US. Several participants are expected to be aged 60 years and above or have a comorbidity such as diabetes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena